Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT05632523

Early Pharmacological and Immune Monitoring After Conversion to Belatacept in Renal Transplant Patients

Conditions: Renal Transplant, Conversion

Sex: All

Ages: 18 Years – N/A

Enrollment: 15

Sponsor: University Hospital, Tours

Location: France

Summary

Single-center, prospective, translational, clinical-biological, multidisciplinary study

Eligibility Criteria

Inclusion Criteria:Age ≥ 18 yearsRenal transplant patientPatient converted from an anticalcineurin to belataceptExclusion Criteria:Opposition to data processingHemoglobin < 9g/dLPatient under judicial protectionPregnant or breastfeeding woman

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05632523). StuddyBuddy aggregates publicly available trial information.